GO
Loading...

Enter multiple symbols separated by commas

Dyax Says Genetic Disease Drug Meets Goals; Shares Surge

Dyax said its product candidate for hereditary angioedema, a genetic disease, met its main goal in a late-stage trial, sending the biopharmaceutical company's shares up more than 40% in after-hours trading.

The drug, codenamed DX-88, achieved statistically significant results for both the primary and secondary endpoints, Dyax said in a statement.

Hereditary angioedema is characterized by episodes of acute swelling and inflammation.

The company said the overall safety results showed that the drug continues to be well tolerated.

Dyax said it will present more detailed results next week.

Shares of the company rose to $5.87 in late electronic trading, after closing at $4.00 Thursday on the Nasdaq.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Should Greeks bet on Bitcoin?

    Brian Armstrong, Coinbase CEO, is waving fees for the next week for customers buying and selling with euros. He joins Squawk Alley to discuss Bitcoin and opportunities it may have for payments.

  • Company shames you into using less water

    Company shames you into using less water by showing how you measure up to your neighbors and California water agencies are buying their software like crazy. CNBC's Jane Wells takes a closer look.

  • ADP & ISM: Is less really more?

    Will less from the economy bring more from the Fed? CNBC's Rick Santelli reports his outlook.